Zealand Pharma A/S (ZLDPF)

Market Cap	4.51B -38.5%
Revenue (ttm)	1.44B +11,809.7%
Net Income	1.03B
EPS	14.40
Shares Out	n/a
PE Ratio	4.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138
Average Volume	2,815
Open	63.84
Previous Close	n/a
Day's Range	63.84 - 63.84
52-Week Range	49.98 - 108.30
Beta	0.48
RSI	39.69
Earnings Date	Feb 19, 2026

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 440
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZLDPF

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.

Financial numbers in DKK